| Abstract |
Objective: To study the effect of chymotrypsin combined with terbutaline nebulization in the treatment of bronchial asthma. Method: 120 patients with bronchial asthma admitted between January 2019 and January 2022 were selected as the observation subjects for this experiment. They were divided into two groups by shaking the swab. 60 patients with long swabs were selected as the combination group and treated with chymotrypsin combined with terbutaline nebulization. 60 patients with short swabs were selected as the nebulization group and treated with terbutaline nebulization. The symptom disappearance time, lung function, serum inflammatory index levels, and immunoglobulin levels of bronchial asthma patients in the combination group and nebulization group were compared. Result: There was a significant difference in the disappearance time of symptoms between the combination group and the nebulization group. The combination group had a shorter disappearance time for symptoms such as cough, chest tightness, wheezing, and wheezing, with statistical significance (P<0.05). There was a significant difference in lung function indicators between the combination group and the nebulization group, with the combination group having stronger lung function and statistical significance (P<0.05). Before treatment, the levels of serum inflammatory markers were similar between the combination group and the nebulization group (P>0.05); After treatment, the levels of TNF - α, IL-4, IL-23, ECP, Hs CRP, etc. improved in both the combination group and the nebulization group, while the levels of TNF - α, IL-4, IL-23, ECP, Hs CRP, etc. were more ideal in the combination group, with statistical significance (P<0.05). Before treatment, the immunoglobulin levels in the combination group and the nebulization group were similar (P>0.05); After treatment, the levels of IgG, IgM, IgA, IgE, etc. in both the combination group and the nebulization group improved, and the levels of IgG, IgM, IgA, IgE, etc. in the combination group were more ideal, with statistical significance (P<0.05). Conclusion: The combination of chymotrypsin and terbutaline nebulization therapy has a more prominent effect on the treatment of bronchial asthma, promoting the early control of symptoms such as cough, chest tightness, wheezing, and wheezing in patients, improving their quality of life, and is worthy of widespread clinical application.
|